Heart Disease News and Research

Latest Heart Disease News and Research

Pfizer-FRSQ Innovation Fund supports genetic study of inflammatory bowel disease and cancer

The first two research projects supported by the Pfizer-FRSQ Innovation Fund will investigate differences in the genetic code for inflammatory bowel disease and metastatic colorectal cancer. This research could lead to improved diagnosis and the development of individualized treatments for these diseases. These innovative projects are marshalling multidisciplinary teams of seasoned researchers from major Quebec research institutions.

8 Oct 2009

NHLBI awards $11 million to research on the biology of two fatal lung diseases

Researchers at National Jewish Health and four other research centers have been awarded an $11 million, two-year grant from the National Heart Lung and Blood Institute as part of the NIH Recovery Act that will allow a team of national scientists to delve deeply into the biology of two fatal lung diseases for which there are few therapeutic options.

8 Oct 2009

Hoana Medical to be showcased at the FiReGlobal : West Coast conference

FiReGlobal : West Coast is proud to announce that Hoana Medical, Inc. has been selected as a FiReStar company to be featured at the FiReGlobal : West Coast conference. FiReStar companies, both local and global, are pre-selected based on their potential to bring positive change to the world. These companies will be showcased throughout the conference, and at a FiReStar reception, during which local and global investors will be given the chance to meet company officers.

8 Oct 2009

Ethnicity plays a significant role in non-small cell lung cancer genetics: Study

Clinical research out of University Hospitals Case Medical Center has found that African Americans with a common form of lung cancer have a lower frequency of drug-sensitizing genetic mutations, which may impact response to new cancer-fighting drugs.

8 Oct 2009

White House honors PET researcher with National Science Award

Joanna Fowler, Ph.D., a major contributor to brain research and a pioneer in molecular imaging, is being recognized by the White House with the National Medal of Science-the highest award for lifetime achievement in science. Eight other researchers will join Fowler to receive the award at a White House ceremony on October 7.

8 Oct 2009

Antioxidants can contribute to early onset of Type 2 diabetes

An international team of scientists, led by Monash University researchers, has found that anti-oxidants commonly touted for their health-promoting benefits, could contribute to the early onset of Type 2 diabetes.

8 Oct 2009

NIH funds Triple Ring Technologies' X-ray imaging system development

Triple Ring Technologies, Inc., a leading provider of early-stage advanced research and development services, today announced that it has been awarded a Challenge Grant from the National Heart, Lung and Blood Institute (NHLBI), a division of the National Institutes of Health (NIH), as part of the American Recovery and Reinvestment Act (ARRA).

8 Oct 2009

Amarillo Biosciences, Intas Pharmaceuticals enter strategic partnership to combat influenza in India

Amarillo Biosciences, Inc. today announced that it has agreed to a strategic partnership with Intas Pharmaceuticals Limited (Intas), one of the top 20 pharmaceutical companies in India, whereby Intas will sponsor clinical trials of ABI's orally administered interferon-alpha lozenges in order to combat influenza. Intas will pay ABI a royalty on net sales after marketing approval is obtained in India.

8 Oct 2009

MENA's diabetes action plan to improve the prevention, treatment and care of diabetes

International Diabetes Federation Middle East and North Africa Region (MENA) today launched a diabetes action plan, marking a major step forward towards optimal disease management in type 2 diabetes. The MENA action plan aims to improve the prevention, treatment and care of diabetes, which has reached epidemic proportions in the region and has overtaken wider communicable diseases as a health risk.

8 Oct 2009

Relypsa commences patient enrollment in Phase 2b clinical trial of RLY5016 for treating hyperkalemia

Relypsa, Inc., today announced the initiation of patient enrollment in the PEARL-HF study, a Phase 2b clinical trial of the company’s lead compound, RLY5016. A novel potassium binder designed for chronic use, RLY5016 is being evaluated in the prevention and treatment of hyperkalemia, for which there are no current satisfactory treatments.

7 Oct 2009

FDA approves Daiichi Sankyo's sNDA for Welchol

Daiichi Sankyo, Inc. (DSI) announced today that the U.S. Food and Drug Administration (FDA) has approved the supplemental new drug application (sNDA) for Welchol® (colesevelam HCl) to be used as an adjunct to diet and exercise for the reduction of elevated low-density lipoprotein cholesterol (LDL-C) in boys and postmenarchal girls, 10 to 17 years of age, with heterozygous familial hypercholesterolemia (heFH) alone or in combination with a statin after failing an adequate trial of diet therapy.

7 Oct 2009

Arizona Heart Institute partners with Arizona Research Center for the advancement of cardiovascular therapies

Arizona Heart Institute, a world leading medical facility specializing in diagnosis, treatment and prevention of heart and vascular disease, and Arizona Research Center, a dedicated provider of clinical research studies, announce a partnership in the advancement of cardiovascular therapies.

7 Oct 2009

New report on the relationship between secondhand smoke and heart disease

The dangers of secondhand smoke have led some organizations and communities to establish smoking bans in offices, restaurants, and other public venues. The effectiveness of such bans in protecting people from health risks associated with breathing environmental tobacco smoke has been a matter of continuing debate.

7 Oct 2009

Aryx Therapeutics to raise up to $35 million from sale of its common stock

ARYx Therapeutics, Inc., a biopharmaceutical company, today announced that it has secured a committed equity financing facility under which it may sell up to $35 million of shares of its common stock to Commerce Court Small Cap Value Fund, Ltd. (“Commerce Court”) over a 24 month period. The maximum number of shares that can be sold by ARYx is specified in the agreement. ARYx is not obligated to utilize any of the $35 million facility and remains free to enter into and consummate other equity and debt financing transactions.

7 Oct 2009

Stereotaxis receives commitment letter from Silicon Valley Bank

Stereotaxis, Inc. today announced that it has received a commitment letter from Silicon Valley Bank, a member company of SVB Financial Group (Nasdaq: SIVB), to increase and extend its credit facility.

7 Oct 2009

The Top 10 Medical Innovations for 2010 announced at Cleveland Clinic Medical Innovation Summit

Cleveland Clinic's Top 10 Medical Innovations for 2010 list features a wide range of new techniques and therapies that are being developed to treat everything from deafness and Parkinson's disease to pneumonia and sleep disorders.

7 Oct 2009

2010 Medco Medicare Prescription Plan to identify lower-cost medication options

Medco Health Solutions, Inc. (NYSE: MHS) is helping seniors in this tough economy find smart solutions for getting the most value out of their Medicare prescription drug plan.

7 Oct 2009

Working Nights Spanish Calendar for Hispanics to improve their security and wellbeing

Circadian Age, Inc. – ‘Working Nights’ – a company dedicated to helping shift workers and their families adjust to their unique lifestyles, is announcing a new Spanish calendar. The 2010 Working Nights Spanish Calendar offers organizations with Hispanic workers the opportunity to show added concern about the health and safety of this group of employees, by providing them with educational material in their own language, to use at home.

7 Oct 2009

Scientists develop new molecule that can deliver genetic-based drugs into cells

Theresa M. Reineke, associate professor of chemistry in the College of Science, and colleagues in her lab at Virginia Tech and at the University of Cincinnati have developed a new molecule that can travel into cells, deliver genetic cargo, and packs a beacon so scientists can follow its movements in living systems.

7 Oct 2009

FDA provides Genzyme a complete response letter for Clolar NDA

Genzyme Corporation announced today that the FDA provided a complete response letter regarding the company's supplemental New Drug Application for Clolar® (clofarabine) in previously untreated older adult patients with acute myeloid leukemia (AML) and at least one unfavorable baseline prognostic factor. The agency recommended a randomized, controlled clinical study be conducted for label expansion of Clolar in this indication.

7 Oct 2009

Heart Disease News and Research

Latest Heart Disease News and Research

Pfizer-FRSQ Innovation Fund supports genetic study of inflammatory bowel disease and cancer

NHLBI awards $11 million to research on the biology of two fatal lung diseases

Hoana Medical to be showcased at the FiReGlobal : West Coast conference

Ethnicity plays a significant role in non-small cell lung cancer genetics: Study

White House honors PET researcher with National Science Award

Antioxidants can contribute to early onset of Type 2 diabetes

NIH funds Triple Ring Technologies' X-ray imaging system development

Amarillo Biosciences, Intas Pharmaceuticals enter strategic partnership to combat influenza in India

MENA's diabetes action plan to improve the prevention, treatment and care of diabetes

Relypsa commences patient enrollment in Phase 2b clinical trial of RLY5016 for treating hyperkalemia

FDA approves Daiichi Sankyo's sNDA for Welchol

Arizona Heart Institute partners with Arizona Research Center for the advancement of cardiovascular therapies

New report on the relationship between secondhand smoke and heart disease

Aryx Therapeutics to raise up to $35 million from sale of its common stock

Stereotaxis receives commitment letter from Silicon Valley Bank

The Top 10 Medical Innovations for 2010 announced at Cleveland Clinic Medical Innovation Summit

2010 Medco Medicare Prescription Plan to identify lower-cost medication options

Working Nights Spanish Calendar for Hispanics to improve their security and wellbeing

Scientists develop new molecule that can deliver genetic-based drugs into cells

FDA provides Genzyme a complete response letter for Clolar NDA

Industry Focus eBook - Medical device (1st edition) eBook

Redefining control and consistency in anaerobic microbiome workflows

AI in Healthcare: How generative tools are transforming clinical practice

The future of automation: Machine learning–driven hepatocyte and organoid counting

Heart Disease News and Research

Latest Heart Disease News and Research

Industry Focus eBook - Medical device (1st edition) eBook

Redefining control and consistency in anaerobic microbiome workflows

AI in Healthcare: How generative tools are transforming clinical practice

The future of automation: Machine learning–driven hepatocyte and organoid counting

Newsletters you may be interested in